Top

Published in:

01-11-2020 | Prostate Cancer | Review

Magnetic resonance imaging of the prostate after focal therapy with high-intensity focused ultrasound

Authors: Soleen Ghafoor, Anton S. Becker, Daniel Stocker, Borna K. Barth, Daniel Eberli, Olivio F. Donati, Hebert Alberto Vargas

Published in: Abdominal Radiology | Issue 11/2020

Abstract

For clinically significant, locally confined prostate cancer, whole-gland radical prostatectomy and radiotherapy are established effective treatment strategies that, however, come at a cost of significant morbidity related to urinary and sexual side effects. The concept of risk stratification paired with a better understanding of prognostic factors has led to the development of alternative management options including active surveillance and focal therapy for appropriately selected patients with localized disease. High-intensity focused ultrasound (HIFU) is one such minimally invasive, image-guided treatment option for prostate cancer. Due to the relative novelty of HIFU and the increased use of magnetic resonance imaging in prostate cancer, many radiologists are not yet familiar with imaging findings related to HIFU, their temporal evolution as well as imaging appearance of recurrent disease after this type of focal therapy. HIFU induces sharply demarcated, localized coagulative necrosis of a tumor through thermal energy delivered via an endorectal or transurethral ultrasound transducer. In this pictorial review, we aim at providing relevant background information that will guide the reader through the general principles of HIFU in the prostate, as well as demonstrate the imaging appearance of expected post-HIFU changes versus recurrent tumor.

Available only for authorised users

Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK (2011) Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 117 (13):2883-2891. https://doi.org/10.1002/cncr.25900CrossRefPubMedPubMedCentral

Bianco FJ, Scardino PT, Eastham JA (2005) Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function (“trifecta”). Urology 66 (5, Supplement):83-94. https://doi.org/10.1016/j.urology.2005.06.116

Mohammed N, Kestin L, Ghilezan M, Krauss D, Vicini F, Brabbins D, Gustafson G, Ye H, Martinez A (2012) Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys 82 (1):204-212. https://doi.org/10.1016/j.ijrobp.2010.10.009CrossRefPubMed

Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ (2013) Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study. European Urology 63 (4):597-603. https://doi.org/10.1016/j.eururo.2012.11.005CrossRefPubMed

Ahdoot M, Lebastchi AH, Turkbey B, Wood B, Pinto PA (2019) Contemporary treatments in prostate cancer focal therapy. Curr Opin Oncol 31 (3):200-206. https://doi.org/10.1097/CCO.0000000000000515CrossRefPubMedPubMedCentral

Hectors SJCG, Jacobs I, Moonen CTW, Strijkers GJ, Nicolay K (2016) MRI methods for the evaluation of high intensity focused ultrasound tumor treatment: Current status and future needs. Magnetic Resonance in Medicine 75 (1):302-317. https://doi.org/10.1002/mrm.25758CrossRefPubMed

Barkin J (2011) High intensity focused ultrasound (HIFU). Can J Urol 18 (2):5634-5643PubMed

Ishihara Y, Calderon A, Watanabe H, Okamoto K, Suzuki Y, Kuroda K, Suzuki Y (1995) A precise and fast temperature mapping using water proton chemical shift. Magn Reson Med 34 (6):814-823. https://doi.org/10.1002/mrm.1910340606CrossRefPubMed

Kirkham APS, Emberton M, Hoh IM, Illing RO, Freeman AA, Allen C (2008) MR Imaging of Prostate after Treatment with High-Intensity Focused Ultrasound. Radiology 246 (3):833-844. https://doi.org/10.1148/radiol.2463062080CrossRefPubMed

10.

Apfelbeck M, Clevert DA, Ricke J, Stief C, Schlenker B (2018) Contrast enhanced ultrasound (CEUS) with MRI image fusion for monitoring focal therapy of prostate cancer with high intensity focused ultrasound (HIFU)1. Clin Hemorheol Microcirc 69 (1-2):93-100. https://doi.org/10.3233/ch-189123CrossRefPubMed

11.

Lotte R, Lafourcade A, Mozer P, Conort P, Barret E, Comperat E, Ezziane M, de Guibert PJ, Tavolaro S, Belin L, Boudghene F, Lucidarme O, Renard-Penna R (2018) Multiparametric MRI for Suspected Recurrent Prostate Cancer after HIFU:Is DCE still needed? Eur Radiol 28 (9):3760-3769. https://doi.org/10.1007/s00330-018-5352-zCrossRefPubMed

12.

Hötker AM, Meier A, Mazaheri Y, Zheng J, Capanu M, Chaim J, Sosa R, Coleman J, Hricak H, Akin O (2019) Temporal changes in MRI appearance of the prostate after focal ablation. Abdom Radiol (NY) 44 (1):272-278. https://doi.org/10.1007/s00261-018-1715-9CrossRef

13.

Berge V, Dickinson L, McCartan N, Hindley RG, Diep LM, Emberton M, Ahmed HU (2014) Morbidity Associated with Primary High Intensity Focused Ultrasound and Redo High Intensity Focused Ultrasound for Localized Prostate Cancer. Journal of Urology 191 (6):1764-1769. https://doi.org/10.1016/j.juro.2013.12.036CrossRef

14.

Guillaumier S, Peters M, Arya M, Afzal N, Charman S, Dudderidge T, Hosking-Jervis F, Hindley RG, Lewi H, McCartan N, Moore CM, Nigam R, Ogden C, Persad R, Shah K, van der Meulen J, Virdi J, Winkler M, Emberton M, Ahmed HU (2018) A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur Urol 74 (4):422-429. https://doi.org/10.1016/j.eururo.2018.06.006CrossRefPubMedPubMedCentral

15.

Rigo M, Mazzola R, Napoli G, Giaj-Levra N, Figlia V, Nicosia L, Ricchetti F, Tomasini D, Bonu ML, Cuccia F, Bellorofonte C, Alongi F (2020) Post-HIFU locally relapsed prostate cancer: high-dose salvage radiotherapy guided by molecular imaging. Radiol Med. https://doi.org/10.1007/s11547-020-01148-4CrossRefPubMed

16.

Finelli A, Van der Kwast T, Ryan P, Bolton D, Fleshner N, Trachtenberg J, Klotz L, Robinette M, Woo H (2011) Salvage Radical Prostatectomy Following Primary High Intensity Focused Ultrasound for Treatment of Prostate Cancer. The Journal of urology 185:862-868. https://doi.org/10.1016/j.juro.2010.10.080CrossRefPubMed

17.

Peretsman S, Brooks J (2017) Salvage robotic prostatectomy following whole gland high-intensity focused ultrasound with a Sonablate 500 device: technical feasibility and safety. J Robot Surg 11 (2):217-221. https://doi.org/10.1007/s11701-016-0649-xCrossRefPubMed

18.

Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR (2018) Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options. J Urol 199 (4):990-997. https://doi.org/10.1016/j.juro.2018.01.002

19.

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouviere O, Schoots IG, Wiegel T, Cornford P (2017) EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 71 (4):618-629. https://doi.org/10.1016/j.eururo.2016.08.003

20.

Crouzet S, Blana A, Murat FJ, Pasticier G, Brown SCW, Conti GN, Ganzer R, Chapet O, Gelet A, Chaussy CG, Robertson CN, Thuroff S, Ward JF (2017) Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients. BJU Int 119 (6):896-904. https://doi.org/10.1111/bju.13766CrossRefPubMed

21.

Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D’Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M (2014) Prostate Cancer, Version 2.2014. 12 (5):686. https://doi.org/10.6004/jnccn.2014.0072

22.

D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama 280 (11):969-974. https://doi.org/10.1001/jama.280.11.969CrossRefPubMed

23.

Reese AC, Pierorazio PM, Han M, Partin AW (2012) Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology 80 (5):1075-1079. https://doi.org/10.1016/j.urology.2012.07.040CrossRefPubMed

24.

Zumsteg ZS, Zelefsky MJ (2012) Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care? Lancet Oncol 13 (6):e259-269. https://doi.org/10.1016/s1470-2045(12)70084-0CrossRefPubMed

25.

Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR (2005) The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173 (6):1938-1942. https://doi.org/10.1097/01.ju.0000158155.33890.e7CrossRefPubMedPubMedCentral

26.

van den Bos W, Muller BG, Ahmed H, Bangma CH, Barret E, Crouzet S, Eggener SE, Gill IS, Joniau S, Kovacs G, Pahernik S, de la Rosette JJ, Rouvière O, Salomon G, Ward JF, Scardino PT (2014) Focal Therapy in Prostate Cancer: International Multidisciplinary Consensus on Trial Design. European Urology 65 (6):1078-1083. https://doi.org/10.1016/j.eururo.2014.01.001CrossRefPubMed

27.

Wysock JS, Lepor H (2018) Optimizing patient selection for focal therapy-mapping and ablating the index lesion. Transl Androl Urol 7 (Suppl 4):S519-s525. https://doi.org/10.21037/tau.2018.03.16CrossRefPubMedPubMedCentral

28.

Burger IA, Muller J, Donati OF, Ferraro DA, Messerli M, Kranzbuhler B, Ter Voert E, Muehlematter UJ, Rupp NJ, Mortezavi A, Eberli D (2019) (68)Ga-PSMA-11 PET/MR Detects Local Recurrence Occult on mpMRI in Prostate Cancer Patients After HIFU. J Nucl Med 60 (8):1118-1123. https://doi.org/10.2967/jnumed.118.221564CrossRefPubMed

29.

Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, Tempany CM, Choyke PL, Cornud F, Margolis DJ, Thoeny HC, Verma S, Barentsz J, Weinreb JC (2019) Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 76 (3):340-351. https://doi.org/10.1016/j.eururo.2019.02.033CrossRefPubMed

30.

Pompe RS, Kühn-Thomä B, Nagaraj Y, Veleva V, Preisser F, Leyh-Bannurah S-R, Graefen M, Huland H, Tilki D, Salomon G (2018) Validation of the current eligibility criteria for focal therapy in men with localized prostate cancer and the role of MRI. World Journal of Urology 36 (5):705-712. https://doi.org/10.1007/s00345-018-2238-2CrossRefPubMed

31.

Vargas HA, Wassberg C, Akin O, Hricak H (2012) MR Imaging of Treated Prostate Cancer. Radiology 262 (1):26-42. https://doi.org/10.1148/radiol.11101996CrossRefPubMedPubMedCentral

32.

Donati OF, Jung SI, Vargas HA, Gultekin DH, Zheng J, Moskowitz CS, Hricak H, Zelefsky MJ, Akin O (2013) Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy? Radiology 268 (2):440-450. https://doi.org/10.1148/radiol.13122149CrossRefPubMedPubMedCentral

33.

Kim CK, Park BK, Lee HM, Kim SS, Kim E (2008) MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol 190 (5):1180-1186. https://doi.org/10.2214/ajr.07.2924CrossRefPubMed

34.

Luzurier A, Jouve De Guibert PH, Allera A, Feldman SF, Conort P, Simon JM, Mozer P, Comperat E, Boudghene F, Servois V, Lucidarme O, Granger B, Renard-Penna R (2018) Dynamic contrast-enhanced imaging in localizing local recurrence of prostate cancer after radiotherapy: Limited added value for readers of varying level of experience. J Magn Reson Imaging 48 (4):1012-1023. https://doi.org/10.1002/jmri.25991CrossRefPubMed

35.

Rouviere O, Girouin N, Glas L, Ben Cheikh A, Gelet A, Mege-Lechevallier F, Rabilloud M, Chapelon JY, Lyonnet D (2010) Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol 20 (1):48-55. https://doi.org/10.1007/s00330-009-1520-5CrossRefPubMed

36.

Muller BG, van den Bos W, Brausi M, Futterer JJ, Ghai S, Pinto PA, Popeneciu IV, de Reijke TM, Robertson C, de la Rosette JJ, Scionti S, Turkbey B, Wijkstra H, Ukimura O, Polascik TJ (2015) Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project. World J Urol 33 (10):1503-1509. https://doi.org/10.1007/s00345-014-1475-2CrossRefPubMedPubMedCentral

37.

Rosenkrantz AB, Hindman N, Lim RP, Das K, Babb JS, Mussi TC, Taneja SS (2013) Diffusion-weighted imaging of the prostate: Comparison of b1000 and b2000 image sets for index lesion detection. Journal of Magnetic Resonance Imaging 38 (3):694-700. https://doi.org/10.1002/jmri.24016CrossRefPubMed

38.

Rouviere O, Lyonnet D, Raudrant A, Colin-Pangaud C, Chapelon JY, Bouvier R, Dubernard JM, Gelet A (2001) MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 40 (3):265-274. https://doi.org/10.1159/000049786CrossRefPubMed

39.

Hung S-W, Lin Y-T, Liu M-C (2018) Multiparametric magnetic resonance imaging of prostate cancer. Urological Science 29 (6):266-276. https://doi.org/10.4103/uros.Uros_57_18CrossRef

40.

Dickinson L, Arya M, Afzal N, Cathcart P, Charman SC, Cornaby A, Hindley RG, Lewi H, McCartan N, Moore CM, Nathan S, Ogden C, Persad R, van der Meulen J, Weir S, Emberton M, Ahmed HU (2016) Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort. Eur Urol 70 (4):668-674. https://doi.org/10.1016/j.eururo.2016.02.054CrossRefPubMed

41.

Mortezavi A, Krauter J, Gu A, Sonderer J, Bruhin J, Reeve KA, Held L, Donati OF, Rupp NJ, Moch H, Sulser T, Eberli D (2019) Extensive Histological Sampling following Focal Therapy of Clinically Significant Prostate Cancer with High Intensity Focused Ultrasound. J Urol 202 (4):717-724. https://doi.org/10.1097/ju.0000000000000298CrossRefPubMed

42.

Bass R, Fleshner N, Finelli A, Barkin J, Zhang L, Klotz L (2019) Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer. J Urol 201 (1):113-119. https://doi.org/10.1016/j.juro.2018.07.040CrossRefPubMed

43.

Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R, Johnston D, Chen M (2000) A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 163 (1):152-157CrossRef

44.

De Visschere PJ, Naesens L, Libbrecht L, Van Praet C, Lumen N, Fonteyne V, Pattyn E, Villeirs G (2016) What kind of prostate cancers do we miss on multiparametric magnetic resonance imaging? Eur Radiol 26 (4):1098-1107. https://doi.org/10.1007/s00330-015-3894-xCrossRefPubMed

45.

Barret E, Harvey-Bryan KA, Sanchez-Salas R, Rozet F, Galiano M, Cathelineau X (2014) How to diagnose and treat focal therapy failure and recurrence? Curr Opin Urol 24 (3):241-246. https://doi.org/10.1097/mou.0000000000000052CrossRefPubMed

46.

Huber PM, Afzal N, Arya M, Boxler S, Dudderidge T, Emberton M, Guillaumier S, Hindley RG, Hosking-Jervis F, Leemann L, Lewi H, McCartan N, Moore CM, Nigam R, Odgen C, Persad R, Thalmann GN, Virdi J, Winkler M, Ahmed HU (2020) PSA Criteria to Diagnose Failure of Cancer Control following Focal Therapy for Non-metastatic Prostate Cancer Using High Intensity Focused Ultrasound. J Urol:101097ju0000000000000747. https://doi.org/10.1097/ju.0000000000000747

47.

Berman RM, Brown AM, Chang SD, Sankineni S, Kadakia M, Wood BJ, Pinto PA, Choyke PL, Turkbey B (2016) DCE MRI of prostate cancer. Abdominal Radiology 41 (5):844-853. https://doi.org/10.1007/s00261-015-0589-3CrossRefPubMed

48.

Gaur S, Turkbey B (2018) Prostate MR Imaging for Posttreatment Evaluation and Recurrence. Radiol Clin North Am 56 (2):263-275. https://doi.org/10.1016/j.rcl.2017.10.008CrossRefPubMed

49.

Felker ER, Raman SS, Lu DSK, et al. (2019) Utility of Multiparametric MRI for Predicting Residual Clinically Significant Prostate Cancer After Focal Laser Ablation. American Journal of Roentgenology 213(6):1253–1258. https://doi.org/10.2214/AJR.19.21637CrossRefPubMed

50.

McCammack KC, Raman SS, Margolis DJ (2016) Imaging of local recurrence in prostate cancer. Future Oncology 12 (21):2401-2415. https://doi.org/10.2217/fon-2016-0122CrossRefPubMed

51.

Kim CK, Park BK, Park W, Kim SS (2010) Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience. Abdom Imaging 35 (2):246-252. https://doi.org/10.1007/s00261-008-9495-2CrossRefPubMed

52.

Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI, Hricak H (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231 (2):379-385. https://doi.org/10.1148/radiol.2312030011CrossRefPubMed

53.

Kongnyuy M, Halpern DM, Kosinski KE, Katz AE (2017) Cryosurgery, an alternative treatment option for organ-confined prostate cancer: current beliefs and practice patterns of urologists. Int Urol Nephrol 49 (1):43-48. https://doi.org/10.1007/s11255-016-1440-7CrossRefPubMed

54.

Dickinson L, Ahmed HU, Hindley RG, McCartan N, Freeman A, Allen C, Emberton M, Kirkham AP (2017) Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer. Urol Oncol 35 (1):30.e39-30.e15. https://doi.org/10.1016/j.urolonc.2016.07.015

55.

Schmid FA, Schindele D, Mortezavi A, Spitznagel T, Sulser T, Schostak M, Eberli D (2020) Prospective multicentre study using high intensity focused ultrasound (HIFU) for the focal treatment of prostate cancer: Safety outcomes and complications. Urologic Oncology: Seminars and Original Investigations 38 (4):225-230. https://doi.org/10.1016/j.urolonc.2019.09.001CrossRefPubMed

56.

Rischmann P, Gelet A, Riche B, Villers A, Pasticier G, Bondil P, Jung J-L, Bugel H, Petit J, Toledano H, Mallick S, Rouvière O, Rabilloud M, Tonoli-Catez H, Crouzet S (2017) Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate Cancer: A Prospective Multicentric Hemiablation Study of 111 Patients. European Urology 71 (2):267-273. https://doi.org/10.1016/j.eururo.2016.09.039CrossRefPubMed

57.

Feijoo ERC, Sivaraman A, Barret E, Sanchez-Salas R, Galiano M, Rozet F, Prapotnich D, Cathala N, Mombet A, Cathelineau X (2016) Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes. European Urology 69 (2):214-220. https://doi.org/10.1016/j.eururo.2015.06.018CrossRefPubMed

58.

Maestroni U, Dinale F, Minari R, Salsi P, Ziglioli F (2012) High-Intensity Focused Ultrasound for Prostate Cancer: Long-Term Followup and Complications Rate. Advances in Urology 2012:960835. https://doi.org/10.1155/2012/960835CrossRefPubMedPubMedCentral

59.

Fiaschetti V, Manenti G, Di Poce I, Fornari M, Ricci A, Finazzi Agro E, Simonetti G (2012) A Rectourethral Fistula due to Transrectal High-Intensity Focused Ultrasound Treatment: Diagnosis and Management. Case Rep Radiol 2012:962090. https://doi.org/10.1155/2012/962090CrossRefPubMedPubMedCentral

60.

Tonolini M, Bianco R (2012) Multidetector CT cystography for imaging colovesical fistulas and iatrogenic bladder leaks. Insights into Imaging 3 (2):181-187. https://doi.org/10.1007/s13244-011-0145-9CrossRefPubMedPubMedCentral

61.

Ravichandran S, Ahmed HU, Matanhelia SS, Dobson M (2008) Is There a Role for Magnetic Resonance Imaging in Diagnosing Colovesical Fistulas? Urology 72 (4):832-837. https://doi.org/10.1016/j.urology.2008.06.036CrossRefPubMed

62.

Bloom JB, Gold SA, Hale GR, Rayn KN, Sabarwal VK, Bakhutashvili I, Valera V, Turkbey B, Pinto PA, Wood BJ (2018) “Super-active surveillance”: MRI ultrasound fusion biopsy and ablation for less invasive management of prostate cancer. Gland Surgery 7 (2):166-187CrossRef

63.

Thüroff S, Chaussy G, Kiel H (2003) Transrectal focused ultrasound (HIFU) in prostate cancer. European Urology Supplements 2 (1):135. https://doi.org/10.1016/S1569-9056(03)80533-XCrossRef

64.

Netsch C, Bach T, Gross E, Gross AJ (2011) Rectourethral fistula after high-intensity focused ultrasound therapy for prostate cancer and its surgical management. Urology 77 (4):999-1004. https://doi.org/10.1016/j.urology.2010.10.028CrossRefPubMed

65.

Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Annals of Surgical Oncology 17 (6):1471-1474. https://doi.org/10.1245/s10434-010-0985-4

66.

Boutier R, Girouin N, Cheikh AB, Belot A, Rabilloud M, Gelet A, Chapelon J-Y, Rouvière O (2011) Location of residual cancer after transrectal high-intensity focused ultrasound ablation for clinically localized prostate cancer. BJU International 108 (11):1776-1781. https://doi.org/10.1111/j.1464-410X.2011.10251.xCrossRefPubMed

67.

Anttinen M, Mäkelä P, Suomi V, Kiviniemi A, Saunavaara J, Sainio T, Horte A, Eklund L, Taimen P, Sequeiros RB, Boström PJ (2019) Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer. Scandinavian Journal of Urology 53 (5):295-302. https://doi.org/10.1080/21681805.2019.1660707CrossRefPubMed

68.

Yap T, Ahmed HU, Hindley RG, Guillaumier S, McCartan N, Dickinson L, Emberton M, Minhas S (2016) The Effects of Focal Therapy for Prostate Cancer on Sexual Function: A Combined Analysis of Three Prospective Trials. European Urology 69 (5):844-851. https://doi.org/10.1016/j.eururo.2015.10.030CrossRefPubMed

69.

Shoji S, Nakano M, Fujikawa H, Endo K, Hashimoto A, Tomonaga T, Terachi T, Uchida T (2015) Urethra-sparing high-intensity focused ultrasound for localized prostate cancer: Functional and oncological outcomes. International Journal of Urology 22 (11):1043-1049 https://doi.org/10.1111/iju.12876CrossRefPubMed

Title: Magnetic resonance imaging of the prostate after focal therapy with high-intensity focused ultrasound
Authors: Soleen Ghafoor
Anton S. Becker
Daniel Stocker
Borna K. Barth
Daniel Eberli
Olivio F. Donati
Hebert Alberto Vargas
Publication date: 01-11-2020
Publisher: Springer US
Keywords: Prostate Cancer
Magnetic Resonance Imaging
Ultrasound
Magnetic Resonance Imaging
Prostate Cancer
Ultrasound
Published in: Abdominal Radiology / Issue 11/2020
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-020-02577-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Magnetic resonance imaging of the prostate after focal therapy with high-intensity focused ultrasound

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2020

Response to letter to the editor

Contrast-enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid

Fournier gangrene: pictorial review

Other types of diffuse liver disease: is there a way to do it?

Intrahepatic cholangiocarcinoma: pathogenesis, current staging, and radiological findings

Commentary: Ureteral pseudodiverticulosis is diagnosable on computed tomography

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page